BRISTOL-MYERS SQUIBB CO (BMY)

US1101221083 - Common Stock

58.87  +0.64 (+1.1%)

After market: 58.83 -0.04 (-0.07%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

BRISTOL-MYERS SQUIBB CO

NYSE:BMY (11/22/2024, 8:26:32 PM)

After market: 58.83 -0.04 (-0.07%)

58.87

+0.64 (+1.1%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month42.75%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap119.40B
Shares
PE50.32
Fwd PE8.32
Dividend Yield4.12%
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BMY Daily chart

Company Profile

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The firm's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.

Company Info

BRISTOL-MYERS SQUIBB CO

Route 206 And Province Line Road

Princeton NEW JERSEY 10016

P: 16092524621

CEO: Giovanni Caforio

Employees: 34100

Website: https://www.bms.com/

BMY News

News Imagea day ago - Investor's Business DailyAbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback

AbbVie's schizophrenia treatment, courtesy of its Cerevel takeover, missed the market in two studies. But an analyst says there's still more to like.

News Image3 days ago - The Motley FoolIs Bristol Myers Squibb Stock a Buy?
News Image3 days ago - The Motley FoolWant Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks
ChartMill News Image4 days ago - ChartmillTop S&P500 movers in Tuesday's session

Top movers analysis one hour before the close of the markets of S&P500 on 2024-11-19: top gainers and losers in today's session.

News Image5 days ago - Bristol Myers SquibbBristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
News Image9 days ago - Bristol Myers SquibbBristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

BMY Twits

Here you can normally see the latest stock twits on BMY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example